NewsMeter
$1,307,300: that is the unaudited net loss Niki BioSolutions, Inc. (NIKI) recorded for the six months ended June 30, 2026, per an 8-K filed with the SEC.
The math: $1,414,560 in total operating expenses less $107,260 in net other income, with a $164,000 warrant fair-value gain providing the offset.
Against the year-ago period's $449,295 loss, that is a 191% YoY deterioration. Where the loss went The sharpest line is R&D.
Research and development expenses reached $383,752 in H1 2026, up from $19,375 in H1 2025, a near-20x move in one year.
Keep reading